Interestingly, recent case report described that CD19-CAR T cells are able to induce remission in t(8;21) AML patient [63] suggesting that in addition to BP-CML, this therapy modality could be effective in other RUNX1mut leukemia. This evidence concerns the gene CD19 and chronic myelogenous leukemia, BCR-ABL1 positive.